文献速递免疫规划慢病防控与筛查

澳大利亚带状疱疹减毒活疫苗引入2年后的效果评估

Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia.
PubMed 文献 · Vaccine · 2021-02-10

研究利用澳大利亚全科医学数据库MedicineInsight中2017和2018年70-79岁常规就诊者队列,采用Cox比例风险模型评估带状疱疹减毒活疫苗效果。结果显示项目第一年疫苗效果为63.5%(95%CI:47.5,74.6),第二年降至48.2%(95%CI:30.0,61.7),提示免疫效果随时间衰减。

要点

  • 带状疱疹减毒活疫苗在项目第一年效果为63.5%,第二年降至48.2%。
  • 疫苗效果在不同年龄、性别、合并症及就诊频率间无显著差异。
  • 研究提示需进一步评估项目效果,关注免疫衰减。

核心结论

  • 带状疱疹减毒活疫苗效果与其它国家估计一致,但项目第一年后效果出现衰减。

研究设计与样本

  • 基于MedicineInsight全国全科医学数据库的回顾性队列研究,纳入2017年队列40,275人和2018年队列41,735名70-79岁常规就诊者,使用Cox比例风险模型估计疫苗效果并调整年龄、性别等混杂因素。

主要发现

  • 2017年队列疫苗接种者发病密度为3.6/1000人年(35例/9,688人年),未接种者为8.7/1000人年(264例/30,317人年)。
  • 2018年队列疫苗接种者发病密度为3.9/1000人年(66例/16,716人年),未接种者为6.3/1000人年(156例/24,782人年)。
  • 项目第一年平均接种后约8个月时疫苗效果为63.5%(95%CI:47.5,74.6),第二年平均接种后约18个月时降至48.2%(95%CI:30.0,61.7)。
  • 疫苗效果在不同年龄、性别、合并症存在情况及既往全科就诊频率间无差异(交互作用P>0.05)。

临床怎么用

  • 为70-79岁人群接种带状疱疹减毒活疫苗可在第一年提供中等保护,但需关注第二年的效果衰减。
  • 应继续开展项目评估以监测疫苗长期效果。

局限性

  • 研究基于常规就诊者队列,可能受未测量混杂因素影响。
  • 疫苗效果估计基于平均接种时间,未精确个体接种日期。
  • 未报告不同亚组疫苗效果的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Australian National Herpes Zoster Immunisation Program commenced in November 2016 for people aged 70-79 years old in Australia but vaccine effectiveness (VE) in this setting has not previously been assessed. METHODS: We extracted records from two cohorts of patients aged 70-79 years in 2017 and 2018 respectively who were regular attenders in a nationwide general practice dataset, MedicineInsight. Cox proportional hazards models were used to estimate VE. Models were adjusted for potential confounders including age, sex, and other covariates. Analyses were also stratified by sex, presence of comorbid conditions and number of general practitioner (GP) visits in the previous year. RESULTS: The 2017 cohort included 40,275 regular attenders and the 2018 cohort 41,735. Both cohorts had a mean age of 73.9 years and 52% were women. In 2017, among vaccinated people, over 9,688 person-years of follow-up, 35 cases of zoster were diagnosed giving an incidence of 3.6 per 1000 person-years compared to 8.7 per 1000 person-years (264 cases/30,317 person-years) among unvaccinated people. For 2018, among vaccinated people there were 66 incident zoster cases over 16,716 person-years giving an incidence of 3.9 per 1000 person-years compared to 6.3 per 1000 person-years (156 cases/24,782 person-years) among the unvaccinated. Overall, in the first year of the program, when the average time since vaccination was about 8 months, VE was 63.5% (95% CI: 47.5, 74.6) but this fell to 48.2% (95% CI: 30.0, 61.7) in the second year when the average time since vaccination was about 18 months. We found no difference in VE across age, sex, presence of comorbid conditions, and prior GP visit frequency (P-interaction > 0.05). CONCLUSIONS: VE was consistent with that estimated in other countries and international settings. However, our findings suggest waning effectiveness after the first year of the program. Further program evaluation is necessary.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lin J, Dobbins T, Wood JG, et al. Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. Vaccine. 2021. PMID: 33581921. doi:10.1016/j.vaccine.2021.01.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。